The recombinant zoster vaccine (RZV) Shingrix demonstrated effectiveness in preventing herpes zoster (HZ) and postherpetic neuralgia among adults aged 50 years or older with rheumatoid arthritis (RA).
Recombinant quadrivalent influenza vaccine (RIV4) and standard egg-based quadrivalent inactivated IV (IIV4) show comparable effectiveness in reducing influenza-related hospitalization among older ...
Herpes zoster (HZ) is common in older people, with a lifetime risk of 25%. The main risk factors are advanced age and immunosuppression. People with a rheumatic and musculoskeletal disease have an ...
Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at ...
Participants were Medicare beneficiaries aged 65 years or older with continuous Part D coverage, with no prior RZV vaccination. HealthDay News — Two doses of the recombinant zoster vaccine (RZV) are ...
Among older adults who received at least one dose of the recombinant shingles vaccine, vaccine effectiveness against any herpes zoster-related outcome was 56.1%. Getting a second dose yielded a ...
The incidence of herpes zoster and herpes zoster ophthalmicus increase after age 50, and both are associated with an increased risk of cardiovascular complications. For patients ages 50 and older, the ...
The induction of respiratory mucosal immunity, characterized by secretory IgA (sIgA) and lung-resident memory T (T RM) cells, is essential for establishing robust first-line defence against viruses.
The findings arrive after a swirl of regulatory uncertainty surrounding the trivalent (three-strain) vaccine, mRNA-1010.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results